Peripheral Vascular Function in Obstructive Sleep Apnoea
Peripheral vascular function is impaired in people with obstructive sleep apnoea who are untreated compared with age-, weight- and sex-matched healthy controls.
Obstructive Sleep Apnoea
|Study Design:||Observational Model: Case Control
Time Perspective: Cross-Sectional
|Official Title:||Effects of Obstructive Sleep Apnoea and Its Treatment on Macrovascular and Microvascular Function|
- Flow-mediated dilatation of the brachial artery [ Time Frame: Baseline only ] [ Designated as safety issue: No ]The brachial artery dilator response to a 5-min period of forearm arterial occlusion will be measured using a vascular ultrasound scanner and a 7-MHz linear array probe.
- GTN-mediated dilatation of the brachial artery [ Time Frame: Baseline only ] [ Designated as safety issue: Yes ]The brachial artery vasodilator response to a 400 microgram sublingual dose of glyceryl trinitrate will be measured using vascular ultrasound imaging.
- Forearm skin blood flow response to 5-min proximal-cuff arterial occlusion [ Time Frame: Baseline only ] [ Designated as safety issue: No ]Proximal arterial occlusion will be performed by inflating a blood pressure cuff placed on the upper arm to 200 mmHg for 5 min. After cuff deflation, the skin blood flow response will be measured using laser Doppler flowmetry.
- Forearm skin blood flow response to localised heating at 42 degrees C [ Time Frame: Baseline only ] [ Designated as safety issue: No ]A local heating unit on the forearm will be heated from 33 to 42 degrees C at a rate of 1 degree C every 10 s. Temperature will be held at 42 degrees C for 35 min. The increase in skin blood flow will be measured using a laser Doppler flowmetry probe placed in the centre of the local heating unit.
|Study Start Date:||June 2012|
|Estimated Study Completion Date:||June 2013|
|Estimated Primary Completion Date:||May 2013 (Final data collection date for primary outcome measure)|
Untreated OSA patients
Patients with obstructive sleep apnoea who are untreated
OSA patients highly compliant with CPAP
OSA patients established on CPAP therapy (high compliance, > 80% nightly use for ≥ 4 h per night)
OSA patients poorly compliant with CPAP
OSA patients established on CPAP therapy (poor compliance, 10% < nightly use < 50% or < 4 h per night)
Age and BMI-matched controls
Age and BMI-matched controls without OSA
Obstructive sleep apnoea (OSA) is a chronic respiratory disorder associated with endothelial dysfunction, increased sympathetic activation and increased cardiovascular risk. The standard treatment paradigm is continuous positive airway pressure (CPAP), however, patient adherence to CPAP is variable. It is unclear to what extent that poor adherence to CPAP therapy augments vascular endothelial function and reduces cardiovascular risk compared to excellent adherence. The main aim of this research is to investigate vascular endothelial function in OSA patients who are poorly-adherent to CPAP therapy. Nitric oxide (NO)-mediated, endothelium-dependent macrovascular and microvascular function (by brachial artery flow-mediated dilatation and forearm cutaneous thermal hyperaemia, respectively) and generalised microvascular function (by post-occlusion reactive hyperaemia) will be assessed in three obese OSA patient populations (high-adherence (n=20); low adherence (n=20); and, untreated (n=20)) and age-/BMI-matched OSA-free controls. We will also assess body composition, cardiovascular risk, lipid status and functional capacity. This research will evaluate treatment efficacy in patients who are poorly-adherent to CPAP treatment and could identify whether an alternative approach to their care should be explored.
|Contact: Garry A Tew, PhD||+44(0)email@example.com|
|Contact: James Moss, BSc||+44(0)firstname.lastname@example.org|
|Centre for Sport and Exercise Science, Sheffield Hallam University||Recruiting|
|Sheffield, South Yorkshire, United Kingdom, S102BP|
|Contact: James Moss, BSc +44(0)1142252262 email@example.com|
|Principal Investigator: James Moss, BSc|
|Principal Investigator: Garry A Tew, PhD|
|Sheffield Teaching Hospitals NHS FT||Recruiting|
|Sheffield, South Yorkshire, United Kingdom|
|Contact: Stephen Bianchi, MD Stephen.Bianchi@sth.nhs.uk|
|Principal Investigator: Stephen Bianchi, MD|
|Study Director:||Garry A Tew, PhD||Sheffield Hallam University|
|Principal Investigator:||James Moss, BSc||Sheffield Hallam University|
|Study Director:||Stephen Bianchi, MD||Sheffield Teaching Hospitals NHS FT|